A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Clinical trial NCT05243550 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05243550
Sponsor: UroGen Pharma Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Bladder Cancer Urothelial Carcinoma Urothelial Carcinoma Bladder

Start date: 2022-03-01
Primary completion: 2023-04-26
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.